Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
CELC
$100.39+Infinity%1D
Analyst Views on CELC
Wall Street analysts forecast CELC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 98.43 USD with a low forecast of 70.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast CELC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELC is 98.43 USD with a low forecast of 70.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 102.180
Low
70.00
Averages
98.43
High
115.00
Current: 102.180
Low
70.00
Averages
98.43
High
115.00
Wells Fargo
initiated
$126
2025-12-12
New
Reason
Wells Fargo
Price Target
$126
2025-12-12
New
initiated
Reason
As previously reported, Wells Fargo initiated coverage of Celcuity with an Overweight rating and $126 price target. The firm believes the upcoming VIKTORIA-1 PI3KCA mutant readout is largely de-risked by the wild-type readout and Phase 1. The current stock price doesn't reflect gedatolisib's market opportunity in breast cancer and metastatic castration-resistant prostate cancer is a free call option at these levels, Wells adds.
Wells Fargo
initiated
$126
2025-12-12
New
Reason
Wells Fargo
Price Target
$126
2025-12-12
New
initiated
Reason
Wells Fargo initiated coverage of Celcuity with an Overweight rating and $126 price target.
Wolfe Research
Outperform
initiated
$110
2025-11-17
Reason
Wolfe Research
Price Target
$110
2025-11-17
initiated
Outperform
Reason
Wolfe Research initiated coverage of Celcuity with an Outperform rating and $110 price target. Fresh off a Phase 3 win for gedatolisib in second-line PIK3CA-wt breast cancer, the firm sees additional upside as the PIK3CA-mt readout looks "primed to deliver next year," the analyst tells investors. The firm views Celcuity as "a top-tier acquisition opportunity for big pharma," the analyst added.
H.C. Wainwright
H.C. Wainwright
Buy -> Neutral
downgrade
$77 -> $94
2025-11-17
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$77 -> $94
2025-11-17
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded Celcuity to Neutral from Buy with a price target of $94, up from $77. The shares look "priced for perfection," the analyst tells investors in a research note. The firm says Celcuity shares have appreciated 608% year-to-date. At current levels, there is more downside risk than upside, contends H.C. Wainwright.
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
